{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:33:44Z","timestamp":1770899624613,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100023961","name":"CIBERINFEC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI12\/01217"],"award-info":[{"award-number":["PI12\/01217"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00869"],"award-info":[{"award-number":["PI20\/00869"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2014NextGenerationEU"},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Una manera de hacer Europa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Following a successful pilot study of a three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate, we hypothesized that this strategy would sustain virological efficacy and reduce long-term toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>After a 24-week randomized phase, participants in the A-TRI-WEEK trial (ClinicalTrials.gov NCT01778413) were offered the three-day-per-week regimen. The extension was approved by the Institutional Review Board, and participants provided informed consent; follow-up continued until further participation no longer offered additional clinical or research value. HIV-RNA, CD4 and CD8 cells, blood and urine chemistries, and bone mineral density (BMD) were assessed every 6\u2005months. Treatment failure was defined a priori as virological failure (HIV RNA &amp;gt;1000\u2005copies\/mL once or \u226550\u2005copies\/mL confirmed), discontinuation, or loss to follow-up. Secondary outcomes included changes in lipids, estimated glomerular filtration rate (eGFR), urine protein\/creatinine, and BMD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 61 participants completing the 24-week phase, 59 (97%) entered the extension. After 7 years, 37 (63%) remained free of treatment failure. Only one participant experienced virological failure, following an unintentional treatment interruption, with no resistance mutations detected. All other failures were due to discontinuations (CNS symptoms, n\u200a=\u200a7; BMD decline, n\u200a=\u200a7; drug interactions, n\u200a=\u200a2; regimen preference, n\u200a=\u200a2; cancer, n\u200a=\u200a1; death unrelated, n\u200a=\u200a1; loss to follow-up, n\u200a=\u200a1). Laboratory parameters showed biphasic patterns, with initial stability followed by modest late declines in eGFR and BMD and increases in triglycerides and proteinuria. Most discontinuations occurred in the latter half of follow-up (years 4\u20137).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV\/TDF\/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor\u2013based regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag040","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:41:26Z","timestamp":1768999286000},"source":"Crossref","is-referenced-by-count":0,"title":["Short-cycle three-day-per-week efavirenz\/emtricitabine\/tenofovir disoproxil fumarate therapy: a seven-year extension study"],"prefix":"10.1093","volume":"81","author":[{"given":"Beatriz","family":"Borjabad","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hospital Moises Broggi , Sant Joan Desp\u00ed ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhon","family":"Rojas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Althaia, Xarxa Assistencial Universit\u00e0ria de Manresa , Manresa ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexy","family":"Inciarte","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiu","family":"Sempere","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Chivite","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0894-3711","authenticated-orcid":false,"given":"Ana","family":"Gonz\u00e1lez-Cord\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M","family":"Mosquera","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Hospital Cl\u00ednic-ISGLOBAL-, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-4726","authenticated-orcid":false,"given":"Berta","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Calvo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"de la Mora","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Martinez-Rebollar","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Laguno","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9253-3186","authenticated-orcid":false,"given":"Alberto","family":"Foncillas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Alcami","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Acquired Immunodeficiency Syndrome (AIDS) Immunopathology Unit, National Center for Microbiology, Institute of Health Carlos III , Majadahonda ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-7755","authenticated-orcid":false,"given":"Jos\u00e9 M","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Reial Acad\u00e8mia de Medicina de Catalunya (RAMC) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonsoles","family":"Sanchez-Palomino","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Blanch","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hospital Universitari de Santa Maria , Lleida ,","place":["Spain"]},{"name":"CIBER de Salud Mental (CIBERSAM), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-6545","authenticated-orcid":false,"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednic-IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Reial Acad\u00e8mia de Medicina de Catalunya (RAMC) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"2026021206511035500_dkag040-B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/aid.2022.0168","article-title":"Short cycle, intermittent therapy: a valuable option in selected, virologically suppressed people living with HIV","volume":"40","author":"Lanzafame","year":"2024","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026021206511035500_dkag040-B2","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count\u2013guided interruption of antiretroviral treatment","volume":"355","author":"SMART Study Group","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021206511035500_dkag040-B3","doi-asserted-by":"publisher","first-page":"F33","DOI":"10.1097\/00002030-200310170-00001","article-title":"Failures of 1\u2005week on, 1\u2005week off antiretroviral therapies in a randomized trial","volume":"17","author":"Ananworanich","year":"2003","journal-title":"AIDS"},{"key":"2026021206511035500_dkag040-B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1310\/hct0801-19","article-title":"Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study","volume":"8","author":"Cohen","year":"2007","journal-title":"HIV Clin Trials"},{"key":"2026021206511035500_dkag040-B5","doi-asserted-by":"publisher","first-page":"e10307","DOI":"10.1371\/journal.pone.0010307","article-title":"A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda","volume":"5","author":"Reynolds","year":"2010","journal-title":"PLoS One"},{"key":"2026021206511035500_dkag040-B6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/jac\/dkx434","article-title":"Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial","volume":"73","author":"de Truchis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026021206511035500_dkag040-B7","doi-asserted-by":"publisher","first-page":"e421","DOI":"10.1016\/S2352-3018(16)30054-6","article-title":"Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2\/3 trial","volume":"3","author":"BREATHER (PENTA 16) Trial Group","year":"2016","journal-title":"Lancet HIV"},{"key":"2026021206511035500_dkag040-B8","author":"Hill"},{"key":"2026021206511035500_dkag040-B9","author":"Kekitiinwa"},{"key":"2026021206511035500_dkag040-B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-014-0024-z","article-title":"Single-tablet regimens in HIV therapy","volume":"3","author":"Astuti","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2026021206511035500_dkag040-B11","doi-asserted-by":"publisher","first-page":"e0124279","DOI":"10.1371\/journal.pone.0124279","article-title":"Efavirenz-based regimens in antiretroviral-naive HIV-infected patients: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Kryst","year":"2015","journal-title":"PLoS One"},{"key":"2026021206511035500_dkag040-B12","author":"European AIDS Clinical Society (EACS)"},{"key":"2026021206511035500_dkag040-B13","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026021206511035500_dkag040-B14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1089\/aid.2004.20.1173","article-title":"Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection","volume":"20","author":"Wang","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026021206511035500_dkag040-B15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/01.qai.0000167155.44980.e8","article-title":"Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens","volume":"39","author":"Hawkins","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"2026021206511035500_dkag040-B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/01.qai.0000168882.67942.3f","article-title":"The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing","volume":"39","author":"Back","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021206511035500_dkag040-B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/QAI.0b013e3181427835","article-title":"Bioequivalence of efavirenz\/emtricitabine\/tenofovir disoproxil fumarate single-tablet regimen","volume":"46","author":"Mathias","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021206511035500_dkag040-B18","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400\u2005mg efavirenz versus standard 600\u2005mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"ENCORE1 Study Group","year":"2014","journal-title":"Lancet"},{"key":"2026021206511035500_dkag040-B19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. Tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021206511035500_dkag040-B20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1097\/QAD.0000000000001843","article-title":"A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz\/emtricitabine\/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity","volume":"32","author":"Rojas","year":"2018","journal-title":"AIDS"},{"key":"2026021206511035500_dkag040-B21","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1097\/QAD.0000000000002169","article-title":"Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients","volume":"33","author":"Guardo","year":"2019","journal-title":"AIDS"},{"key":"2026021206511035500_dkag040-B22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026021206511035500_dkag040-B23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/QAI.0b013e31802e2940","article-title":"Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy","volume":"44","author":"Karlstr\u00f6m","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021206511035500_dkag040-B24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/jac\/dkt007","article-title":"Safety and feasibility of treatment simplification to atazanavir\/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir\/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)","volume":"68","author":"Di Giambenedetto","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026021206511035500_dkag040-B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"2026021206511035500_dkag040-B26","volume-title":"Global Update on HIV Treatment 2013: Results, Impact and Opportunities","author":"World Health Organization, UNICEF, UNAIDS","year":"2013"},{"key":"2026021206511035500_dkag040-B27","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026021206511035500_dkag040-B28","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive Abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"2026021206511035500_dkag040-B29","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"2026021206511035500_dkag040-B30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antivir Ther"},{"key":"2026021206511035500_dkag040-B31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/QAI.0000000000001908","article-title":"Efficacy and safety of tenofovir disoproxil fumarate versus low-dose stavudine over 96 weeks: a multicountry randomized, noninferiority trial","volume":"80","author":"Venter","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026021206511035500_dkag040-B32","author":"Chivite"},{"key":"2026021206511035500_dkag040-B33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/jac\/dkaf186","article-title":"Five-days-on-two-days-off (FOTO) versus daily bictegravir\/emtricitabine\/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial","volume":"80","author":"Sun","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026021206511035500_dkag040-B34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/jpm13040583","article-title":"Intermittent bictegravir\/emtricitabine\/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV","volume":"13","author":"Sellem","year":"2023","journal-title":"J Pers Med"},{"key":"2026021206511035500_dkag040-B35","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1096\/fj.14-260315","article-title":"Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project","volume":"29","author":"Leibowitch","year":"2015","journal-title":"FASEB J"},{"key":"2026021206511035500_dkag040-B36","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"Landman","year":"2022","journal-title":"Lancet HIV"},{"key":"2026021206511035500_dkag040-B37","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1093\/jac\/dkaf307","article-title":"Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015\u201322: experience from an HIV clinic in Paris, France","volume":"80","author":"Sagaon-Teyssier","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026021206511035500_dkag040-B38","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0000000000004212","article-title":"Could reduced dosing maintain more people on antiretrovirals after the sudden cuts in USAID funding? A crisis response","volume":"39","author":"Hill","year":"2025","journal-title":"AIDS"},{"key":"2026021206511035500_dkag040-B39","author":"i-Base Treatment Bulletin"},{"key":"2026021206511035500_dkag040-B40","volume-title":"Adaptation du Traitement Antir\u00e9troviral en Situation de Succ\u00e8s Virologique Chez L\u2019adulte Vivant Avec le VIH: Recommandations de Bonne Pratique","author":"Haute Autorit\u00e9 de Sant\u00e9 (HAS), ANRS, CNS","year":"2024"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag040\/66863441\/dkag040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag040\/66863441\/dkag040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:51:19Z","timestamp":1770897079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag040\/8475187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag040","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag040"}}